ISRCTN77554566已完成不适用
The safety and efficacy of anti-CD20 therapy (rituximab) in systemic sclerosis: an interventional open-label single centre phase I trial
Catholic University of the Sacred Heart (Italy)0 个研究点目标入组 20 人开始时间: 2009年7月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Systemic sclerosis patients aged 18 - 70 years , either sex
- •2. Diffuse cutaneous involvement
- •3. A worsening of skin score higher than 10% despite conventional therapies
排除标准
- •Severe pulmonary and cardiac involvement
研究者
相似试验
招募中
3 期
Efficacy of Rituximab in children with Acute Lymphoblastic LeukemiaCTRI/2017/12/010897All India Institute of Medical Sciences
进行中（未招募）
1 期
Efficacy of Ofatumumab in children with steroid-dependent nephrotic syndrome aEUCTR2018-001042-33-ITIRCCS Istituto Giannina Gaslini160
进行中（未招募）
1 期
Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukaemia (ALL)- MARALL - Monoclonal Antibodies In Recurrent B cell ALL (MARALL)This is a phase I/ II trial to determine the efficacy of intravenous veltuzumab and epratuzmab either individually or together in combination with chemotherapy in patients with recurrent acute lymphoblastic lymphoma.MedDRA version: 9.1 Level: LLT Classification code 10003890 Term: B precursor type acute leukaemiaMedDRA version: 9.1 Level: LLT Classification code 10003917 Term: B-cell type acute leukaemiaEUCTR2008-002286-32-GBQueen Mary Medical University of London27
招募中
4 期
Anti-CD20 Antibodies for Treatment of SLE-PAHSystemic Lupus ErythematosusPulmonary Arterial HypertensionNCT05828147Chinese SLE Treatment And Research Group50
已完成
2 期
Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell LymphomaDiffuse large B-cell lymphomaC83.3C82.4C85.1Follicular lymphoma grade IIIbB-cell lymphoma, unspecifiedDRKS00009416niversitätsmedizin der Johannes Gutenberg-Universität Mainz70